EP Patent

EP4319766A4 — Nadk2 inhibition in cancer and fibrotic disorders

Assigned to Memorial Sloan Kettering Cancer Center · Expires 2025-05-28 · 1y expired

What this patent protects

Patent listed against methotrexate-sodium.

Drugs covered by this patent

methotrexate-sodium (METHOTREXATE SODIUM)

Patent Metadata

Patent number: EP4319766A4
Jurisdiction: EP
Classification: —
Expires: 2025-05-28
Drug substance claim: No
Drug product claim: No
Assignee: Memorial Sloan Kettering Cancer Center
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.